Published by Josh White on 22nd September 2020
(Sharecast News) - Hikma Pharmaceuticals lowered its guidance for 2020 on Tuesday, following a response letter from the US Food and Drug Administration (FDA) over the abbreviated new drug application for its generic version of GlaxoSmithKline's 'Advair Diskus', or fluticasone propionate and salmeterol inhalation powder, it announced on Tuesday.